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Perkaitan polimorfisma 10398 mitokondria DNA dengan kanser payudara
dalam populasi Melayu di Semenanjung Malaysia
Abstrak
Polimorfisma 10398 mitokondria DNA telah didapati berkait dengan kanser payu
dara dalam beberapa populasi. Dalam kajian ini, polimorfisma 10398 mitokondria DNA
telah disaring pada 101 pesakit kanser payu dara wanita Melayu dan 90 wanita yang sihat
sebagai kawalan dengan menggunakan kaedah penjujukan mini. Hasil menunjukkan
perbezaan statistik yang signifikan dengan nilai  P, p = 0.007 (OR, 2.29; 95% CI, 2.252-
4.200) dengan jumlah varian G lebih tinggi (73%) daripada varian A (27%) dalam pesakit
dan juga dalam kawalan (G = 54%, A = 46%). Tisu kanser payudara kemudian dianalisis
menggunakan kaedah immunohistokimia bagi mengkaji perkaitan polimorfisma ini dalam
mempengaruhi aras apoptosis sel. Tiada perbezaan signifikan didapati antara aras
pengekspresan protein pro (Bax) dan anti (Bcl-2) apoptosis antara pesakit yang membawa
varian A ( p = 0.48). Bagaimanapun, terdapat perkaitan yang signifikan antara protein-
protein ini dalam pesakit yang mempunyai varian G (p = 0.016). Hasil ini menunjukkan
polimorfisma 10398 mtDNA mungkin berguna sebagai penanda risiko kanser payu dara
dalam populasi ini.
Association of mitochondrial DNA 10398 polymorphism in breast cancer and
apoptosis in Malay population
Abstract
The mitochondrial DNA 10398 polymorphism has been observed to associate with
breast cancer in several populations. In this study, mitochondrial DNA 10398 polymorphism
was screened in 101 Malay female patients with invasive breast cancer and 90 age-matched
healthy female controls using minisequencing method. The results showed a statistically
significant difference with P value of p = 0.007 (OR, 2.29; 95% CI, 1.252-4.200) with the
proportion of G variant was higher (73%) than A variant in patients (27%) as well as in
controls (G = 54%, A = 46%). The breast cancer tissues were then analyzed using
immunohistochemistry method to investigate the relation of this polymorphism in affecting
apoptotic level in breast cancer. No significant difference was observed between the
expression of pro (Bax) and anti-apoptotic (Bcl-2) proteins among patients carrying A
variant (p = 0.48).  However, significant difference was observed in patients with G variant
(p = 0.016). These results indicate that mtDNA 10398 polymorphism may be useful as a
breast cancer risk marker in this population.
CHAPTER 1
INTRODUCTION
1.1 Human Genome
The human cell consists of two interdependent genomes; the nuclear genome which
specializes in cellular and tissue structure, and mitochondrial genome which specializes in
energy production (Figure 1.1). Nuclear DNA (nDNA) differs from mitochondrial DNA
(mtDNA) in its location, sequence, quantity in the cell and mode of inheritance. Nuclear
DNA which is located within the nuclei of the cell constitutes of 23 pairs of chromosomes.
Half of the genome is inherited from the biological mother and another half from the
biological father. On the other hand, mitochondrial DNA is found within the mitochondria
organelle with hundreds to thousands of copies per cell and inherited maternally (Giles et
al., 1980).
1.1.1 Mitochondrial genome
Mitochondria (singular mitochondrion) are located in the cytoplasm outside the nucleus of
the cell. They are known to evolve from prokaryotic organisms based on the endosymbiotic
theory (Sagan, 1967; Raven, 1970; Kuntzel and Kochel, 1981; Yang et al., 1985).
Mitochondria are bacterium size organelle (0.5 x 1.0 µm), mobile and capable of profound
changes in size, shapes and location (Avers et al., 1969; Sohal and Bridges, 1978; Knight et
al., 1981). The numbers of mitochondria varies by organism and tissue type. Several cells
have only single mitochondrion and some contain thousands of mitochondria. Eukaryotic
cells typically contain about 2,000 mitochondria which is one fifth of the total cell volume.
Figure 1.1: Nuclear and mitochondrial genome in human cell.
(Modified from http://www.thescienceexperts.com [Accessed on 5th October 2008];
http://www.pauldos.com/musings/main.php [Accessed on 9th May 2008] and
http://www.micro.magnet.fsu.edu/cells/animals/nucleus.html) [Accessed on 24th January
2009]
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The mitochondria are ellipsoidal bodies bounded by a smooth outer membrane and an
extensively invaginated inner membrane that divides the mitochondria into two components;
intermembrane space and matrix. Cristae are formed by the infoldings of the intermembrane
that expand the surface area. On this site, food (sugar) is combined with oxygen to produce
energy (ATP) for the cell. The matrix is a gel-like solution containing high concentrations of
soluble enzymes of oxidative metabolism as well as substrates, nucleotides cofactors and
several copies of DNA which are known as mitochondrial DNA (mtDNA) (Margulis, 1981;
Voet et al., 1998; Lodish et al., 1999).
mtDNA is a double stranded circular molecule of 16,569 base pair (bp) (Brown et al., 1978;
Wiesner et al., 1992). The entire mtDNA were first sequenced in 1981 in Frederick Sanger’s
lab in Cambridge, first authored by Stan Anderson. Resequencing of mtDNA was performed
later to eliminate minor errors and the revised version is known as the Cambridge Reference
sequence (CRS). mtDNA apparently are lack of protective histones and due to the paucity of
DNA repair mechanism, the rate of mutation in mtDNA is calculated to be about ten times
greater compared to the nDNA (Monnat and Loeb, 1985;Yakes and Van Houten, 1997).
This high mutation rate leads to a high variation between mitochondria, not only among
different species but even within the same species (Winstead, 2002).
This bioenergetics molecule consists of two regions which are the coding and control region
(Figure 1.2). The coding region codes for 37 genes. From these 37 genes, 2 genes code for
12S and 16S ribosomal RNAs and 22 for transfer RNA. The RNAs help in assembling
protein building blocks (amino acid) into functioning proteins (Ingman et al., 2000). The
remaining 13 genes codes for the electron transport chain subunits which are complex I
(NADH dehydrogenase), complex III (ubiquinol: cytochrome C oxyreductase), complex IV
(cytochrome C oxidase) and complex V (ATP synthase).
Figure 1.2: Mitochondrial DNA map.
(Modified from http://www.alphabiolab.com/page4/files/picture-12.png) [Accessed on 28th
January 2009]
The control region which is also known as D-loop or non-coding region constitutes 7% of
the mitochondrial genome with 1,124 base pair (bp) in size (16,024-576). This region is
made up of three important regions; i) Hypervariable region I (HV1) expands from
nucleotide position (np) 16,024-16,383 ii) Hypervariable region II (HV2) from np 57-372
and iii) Hypervariable region III (HV3) from np 438-574.
mtDNA comprised of 2 strands, Cytosine-rich light (L)-strand and Guanine-rich heavy (H)-
strand. Each strand are transcribed from one predominant promoter, PL (for L-strand) and
PH (for H-strand), located at the control region (Chang and Clayton, 1984; Chang and
Clayton, 1986). This region also contained the origin of replication for the H-strand (OH)
which begins with the synthesis of a daughter H-strand in a continuous and unidirectional
fashion. This results in displacement of the parental H-strand. After 2/3 of the parental H-
strand has been displaced, the L-strand becomes exposed as a single-stranded and the
synthesis of L-strand begins in an opposite direction.
1.1.2 Mitochondria as cellular power plants
Mitochondria are the indispensable energy producers of human cells. There are at least 87
proteins involved in oxidative energy production. A total of 13 proteins are encoded by the
mtDNA. The remainders are coded by the nuclear DNA which are synthesized in the cytosol
and imported into the mitochondria (Leaver et al., 1983).
Oxidative phosphorylation is a process where a cells’ main energy, adenosine triphosphate
(ATP), is created to allow cells to proliferate, be motile and generate signals for tissues and
organs to function appropriately. The oxidative process is accomplished by series of protein
complexes including coenzymes and cytochromes known as respiratory chain (Figure 1.3).
Figure 1.3: Oxidative phosphorylation and electron transport represent a series of
multisubunit complexes within the mitochondrial inner membrane.
(Available from http://www2.nau.edu/~fpm/bio205/chapter5.2.html.) [Accessed on 15th
October 2008]
Electrons generated from NADH which is produced by oxidation of nutrients such as
glucose through citric cycle, enter this array of electron carriers and being shuttled to the
first carrier, NADH dehydrogenase (Complex I). At this site, NADH is oxidized to NAD+,
which returns to the site of the citric acid cycle to be reduced again. Electrons are then
shuttled to complex III (ubiquinol-cytochrome C reductase) via ubiquinol that moves freely
along the membrane, then to complex IV, where oxygen is reduced to form H2O by the
electrons mobilized by a protein electron carrier, cytochrome C. As electron flows along the
protein complexes, a high concentration of protons are pumped from the mitochondrial
matrix to the intermembrane space at three complexes (I, III and IV), creating a hydrogen
ion (H+) gradient. At the final step in the multiprotein complex V (ATP synthase), such a
gradient is utilized as energy source to synthesize ATP energy, condensation of ADP by
attaching phosphorus atoms to ADP molecules to form ATP. The ATP is subsequently
transported out of the mitochondrial matrix through a special channel. This final-energy
producing process is called the oxidation phosphorylation process (Saraste et al., 1999;
Cohen and Gold, 2001; Denniston et al., 2001; Ballinger, 2005).
1.1.3 Mitochondria integrate apoptosis
Apoptosis is a term introduced by Kerr, Wylie and Currie (1972) describing a programmed
cell death process. Apoptosis is a Greek word meaning a natural cell death (Kerr et al.,
1972). Apoptotic cells show a very characteristic morphology. The membrane of cells
undergoing apoptosis at the early stage will shrink causing lose of interaction with the
normal neighbouring cells. The cytoplasm appears dense, and the organelles are tightly
packed. The cell’s chromatin undergoes condensation followed by compaction of chromatin
to the nucleus membrane before fragmentation. Due to the degradation of DNA, the nucleus
breaks into several discrete chromatin bodies or nucleosomal units. The cell membrane
shows irregular buds known as blebs and makes it breaks apart into several vesicles called
apoptotic bodies, which are then phagocytosed (Newmeyer et al., 1994). The organelle’s
morphology was maintained, even though cell’s cytoplasm was condensed (Figure 1.4).
Apoptosis is controlled by a diverse range of cell signals, either extracellularly or
intracellularly. Extracellular signals may include hormones, growth factors or cytokines
while intracellular initiation of apoptosis may be in response of stress, specifically
mitochondrial stress.
Mitochondria is considered as a key organelle regulating apoptosis since pro-apoptosis
protein such as cytochrome C, AIF, endogenous G or SMAC (second mitochondria-derived
activator caspases) resides in the mitochondria (Liu et al., 1996; Kluck et al., 1997; Shimizu
et al., 1999). Upon receiving signals, these pro-apoptotic proteins trigger a series of
biochemical events leading to activation of apoptosis signaling cascades (Figure 1.5).
The release of cytochrome C from the mitochondria, due to increased permeability of the
outer membrane, activates the apoptotic cascade in the presence of ATP and dATP.
Cytochrome C binds to Apaf-1 (pro-apoptotic protease activating factor) that is free floating
in the cell’s cytoplasm using the energy provided by ATP. The complex then binds to pro-
caspase-9, which is also a floating protein. These complexes aggregate to form a protein
complex known as apoptosome. Apoptosome cleaves the pro-caspase to its active form of
caspase-9 and activates other caspases such as the effectors of caspase-3 and caspase-7. The
activation of these caspases cleaves the proteins of mitochondria membrane causing the
membrane to break down and start a reaction of protein denaturation that leads to
phagocytosis of the cell.
Figure 1.4: Morphology of cells undergoing apoptosis and necrosis.
(Available from
http://home.inje.ac.kr/~lecture/immunology/immch2immtissue/immch2.htm) [Accessed on
28th October 2008]
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Figure 1.5: Apoptosis activation by intrinsic or extrinsic pathways.
(Available from http://www.apoptosisworld.com) [Accessed on 14th October 2008]
1.1.3.1 Mediation of ROS induces apoptosis
Reactive oxygen species (ROS) is a natural byproduct of the normal metabolism of oxygen
in the electron transport chain (Boveris, 1973; Turrens, 2003). During the electron
mobilization, although the oxygen reduction by cytochrome oxidase at complex I and III is
almost orchestrated with great rapidity and precision, 1-4% electron may occasionally
escape or leak. Normally, electron within each orbital of oxygen atom is paired with the
same spin of electron.
The leakage of the unpaired electrons will straightly react with oxygen by joining the
electrons of the different spin causing the oxygen to be partially reduced and formed reactive
oxygen species, primarily superoxide anion (O2-•) (Figure 1.6).
At moderate, the elevation of reactive oxygen species (ROS) was known to participate in
mediating cell signaling (Green and Martin, 1995; Higuchi et al., 1998; Suzuki et al., 1999;
Moon et al., 2002). The formation of ROS may reduce cytochrome C in the intermembrane
space, or converted to oxygen and H2O2 in both matrix and intermembrane. Bcl-2 protein at
the surface of the mitochondria membrane will detect these damages and activates protein
Bax, a pro-apoptotic protein, and punch holes at the mitochondrial membrane to release the
cytochrome C (Yang et al., 1997; Shimizu et al., 1999). As described in Section 1.1.3, the
released cytochrome C will induce the cell signaling.
1.1.3.2 Key elements of Apoptosis
The Bcl-2 family is among the critical proteins besides ced-9 gene, c-myc gene and tumor
suppressors such as p53 that regulate the release of pro-apoptotic factor, cytochrome C
(Oltvai et al., 1993; Korsmeyer et al., 1993; Craig, 1995; Desagher and Martinou, 2000) and
governed the machinery of the cell death pathway (Boise et al., 1993; Eissa, 1995; Parton et
Figure 1.6: Reactive oxygen species formed by unpaired electrons.
(Available from
http://www.arbl.cvmbs.colostate.edu/hbooks/pathphys/misc_topics/radicals.html) [Accessed
on 27th December 2008]
al., 2001). The Bcl-2 (B-Cell Lymphoma/ Leukemia-2) gene is the pioneering prototype of a
large family of pro-apoptotic such as Bax, Bak, Bad, Bcl-Xs, Bim and Bid, and antiapoptotic
factors such as Bcl-2, Bcl-X, Bcl-W that directly or indirectly regulate apoptosis (Oltvai et
al., 1993; Harrington et al., 1994; Reed, 1996).
Bcl-2 protein is the first anti-apoptotic members of Bcl-2 family identified (Vaux et al.,
1988). Bcl-2 resides in the cytoplasmic surface of outer mitochondrial membrane as well as
in endoplasmic reticulum and nuclear membrane (Monaghan et al., 1992; Krajewski et al.,
1993; Boise et al., 1993; Liu et al., 1996).
Bcl-2 consists of BH1-4 domains which can homodimerize with itself or forms
heterodimerizers with a homologous protein (Yin et al., 1994; Hanada et al., 1995). The pro-
apoptotic members are separate into two structurally distinct subfamilies; multidomain
proteins for example Bax and Bak that consist of BH1-3 domains, and BH3-only proteins
such as Bim and Bid. Bax, which is structurally similar to the anti-apoptotic proteins, is
translocated to the mitochondria prior to apoptosis induction, where it disrupts the
mitochondrial membrane causes the efflux of cytochrome C (Liu et al., 1996; Wolter et al.,
1997; Adams and Cory, 1998; Gross et al., 1999).
The regulation of apoptosis by the Bcl-2 family in response to apoptotic stimuli is defined in
3 different models as propose in Figure 1.7. First, BH-3 only protein will bind to and
neutralizes the anti-apoptotic Bcl-2 which will then releases Bax and Bak. Second, BH3-
only protein displays a selective binding to specific Bcl-2 family and since more than one
BH3-only protein are needed to initiate the releasing of pro-apoptotic proteins, excessive
Bcl-2 may inhibits apoptosis by antagonizing the activated conformation of Bax, preserves
Bax in an inactive conformation and prevents the translocation of the pro-apoptotic protein
to the mitochondria. Third, BH3-only protein may directly bind to and activates Bax protein.
Figure 1.7: Regulation of apoptosis by Bcl-2 family proteins. Death stimuli responses
results in activation of BH3-only protein, which will antagonize with Bcl-2 protein or
directly activate Bax and Bak. Dimerization of activated conformation of Bax and Bak with
Bcl-2 disrupts mitochondrial membrane potential causes the efflux of cytochrome c and
activate the death pathway. Opposed function took place when excessive Bcl-2 occurred
where Bcl-2 protein will associates with the activated conformation of Bax and block the
flux of cytochrome C.
Death stimuli
(mtDNA stress)
BH3-only protein
Bcl-2 Bax, Bak
(when in excess)
Apoptosis
The conformational changes of Bax and Bak, enables them to integrate into mitochondrial
membrane, allowing various degrees of dimerization with Bcl-2 proteins and results in
release of pro-apoptotic factor, cytochrome C which leads to activation of caspases pathway
followed with cell death (Oltvai et al., 1993; Wolter et al., 1997; Shore and Viallet, 2005).
The ratio between anti- and pro-apoptotic proteins is crucial to dictate cell’s sensitivity
towards apoptosis (Green and Martin, 1995; Komaki et al., 1998; Parton et al., 2001). Over
expressed of Bax counters the death repressor action of Bcl-2 and accelerates apoptosis
(Oltvai et al., 1993; Hunter and Parslow, 1996) while over expressed of Bcl-2 will induce
cell survival that leads to carcinogenesis (Beger et al., 2002; Tombor et al., 2003; Zunfu et
al., 2005). In humans, Bcl-2 has been a good prognostic feature in breast cancer since it was
expressed in about 80% of breast cancers. This is supported by a study by Bargou et al.,
(1995), showing that levels of pro-apoptotic protein, Bax, were reduced in breast tumor
compared to the normal tissue whereas an appropriate balance of pro-apoptotic and anti-
apoptotic proteins is present in normal tissue.
1.1.4 Mitochondria DNA dysfunction
Alterations in mtDNA genes or in nuclear genes, that are most likely controlling mtDNA
replication and encode numbers of mitochondrial enzyme, will interrupt and inhibit their
normal functions. Most mtDNA mutations which lead to mitochondrial dysfunction is
increasingly recognized as an important cause of human pathology such as in cancers, since
80% of mtDNA codes functional proteins (Zeviani and Di Donato, 2004; Taylor and
Turnbull, 2005; Nomura et al., 2007).
Mitochondrial DNA is more prone to somatic mutations. The accumulation of somatic
mutations may induce mitochondrial exposure to ROS and leads to errors in the mtDNA-
encoded polypeptides which later affect the complexes of the mitochondrial electron
transport chain (Yakes and Van Houten, 1997; Droge, 2002). Under normal conditions
where the rates of ROS production and scavenging capacity are essentially constant and in
balance, cell and tissues are in stable state. However, oxidative stress generated by
environmental factors, will increased the leakage of ROS. Practically, amino acids may
serve as target of oxidative attack of ROS and caused modifications of proteins. mtDNA is
vulnerable to the effect of these molecules and has limited ability to repair itself due to the
lack of histone proteins and mechanism of repair. Therefore, the excessive formation and
continuous accumulation of ROS contribute to a ‘vicious cycle’ and buildup of additional
mtDNA mutations. The chronic, persistent and extensive ROS exposure may directly or
indirectly damage cellular macromolecule. This could lead to cellular stress response and
inhibit the cell apoptosis, which is essential for tissue development and homeostasis (Yakes
and Van Houten, 1997; Higuchi et al., 1998; Bulkley, 2002). Several findings showed that
defects and reduction in the apoptosis threshold can extend cell life span, contributing to
continuous proliferation that may leads to cancer development (Thompson, 1995; Reed,
1996; Reed, 1999; Lebedeva et al., 2002; Shore and Viallet, 2005). However, the exact role
of mtDNA mutations in inhibiting apoptosis either by suppression of pro-apoptotic genes or
by activation of anti-apoptotic genes has not been defined (Carew and Huang, 2002).
1.1.4.1 Mitochondria DNA dysregulation in cancers
The role of mitochondria in cancer development has been in question recently. The
subsequent accumulation of mtDNA mutations have been suspected in the initiation of
carcinogenesis (Penta et al., 2001; Verma and Kumar, 2007). Different mtDNA mutations
have been identified in different tumor tissues and cell lines, including cancers of bladder,
head and neck (Fliss et al., 2000), cervical (Sharma et al., 2005), pancreatic, colorectal (Aral
et al., 2006), breast (Tseng et al., 2006), lung (Jin et al., 2007), prostate (Petros et al., 2005)
and gastric carcinomas (Carew and Huang, 2002). About 48% of mitochondrial instabilities
have been found in 40 pairs of breast cancer tissues (Richard et al., 2000). Substantial data
suggested most of the mitochondrial aberrations resided in the mtDNA-encoded complexes
I, III, IV, V as well as in the hypervariable regions (Penta et al., 2001).
1.2 Cancer
Cancer was known to exist since the early beginning of human history development of
human evolution based on the written record and inspection done on mummies (Pardee and
Reedy, 1986). The term cancer was coined by Hippocrates in the fifth century BC,
describing a family of diseases in which a cell population divides beyond normal process
without restriction until the normal cell space became confluent and metastasize to distant
areas of the body (Coupal, 1927; Kardinal and Yabro, 1979; Gallucci et al., 1985).
Cancerous cells can arise in a variety of tissues and organs, and each of these sites contains
different cell types that may be affected. Cancers are usually classified according to the
tissue from which the cancerous cells originated (Pardee and Reedy., 1986).
1.2.1 Breast Cancer
Breast cancer is a cancer of breast tissue. The breast is a collection of glands (also known as
lobule) and fatty tissue that lies between the skin and the chest wall. The milk glands of each
breast are divided into 15 to 20 lobes, each possessing a duct that runs separately into the
nipple. Typically, most common types of breast cancer originate from the epithelial cells of
the milk glands (ductal carcinoma) or lobe of the milk glands (lobular carcinoma). Breast
cancer is the most common malignancy and the second most fatal cancer in women.
In Malaysia, cancer is a major morbidity and mortality concern. Based on National Cancer
Registry data, Malaysian population is estimated to bear a cancer burden of about 40,000
new cases per year (Looi et al., 2004). Breast cancer is one of the most prevalence cause of
cancer death in Malaysia (Hisham and Yip, 2004; Aina, 2008). The incidence rate for breast
cancer was estimated approximately 1 in 1327 in 2006 and the incidence continues to rise
(Yip et al., 2006). Breast cancer composed 30.4% of all female cancers with 1 in 9 of
Malaysian female having risk for the cancer (Lim et al., 2003). This cancer seems to be
predominant among Chinese followed by Indians and Malays (Omar et al., 2006). A
research showed that family history is among factors that significantly associated with breast
cancer in Malaysian females but do not associated with age (Norsa’adah et al., 2005).
1.2.2 Mutation studies in Breast Cancer
Breast cancer tends to cluster in families. This clustering can be explained by inherited
mutations on specific genes that confer high risk of disease (The Breast Cancer Association,
2006). Several alterations and mutations on certain gene and protein have been conferred in
nuclear and mitochondrial genome with breast cancer susceptibility (Kristensen and
Borresen-Dale, 2000; Richard et al., 2000; Mimori et al., 2002; Beckmann et al., 2007;
Oldenburg et al., 2007). A total of 87.5% of nuclear and mitochondrial DNA instabilities
were found in breast cancer patients (Richard et al., 2000). Today, there is a broad
agreement that there are many genes involved in the process of breast carcinogenesis. The
risk for breast cancer increases with each relevant genetic alteration present. Few definitive
common susceptibility alleles have been associated with breast cancer including the BRCA 1
and BRCA 2, which are known as the tumor suppressor genes, reside in the nuclear DNA
and widely expressed in many tissues (Macdonald et al., 2004; Oldenburg et al., 2007).
Mutations at protein p53 and the ‘guardian of the genome’ TP53 were also frequently
studied in association with breast cancer (Buyru et al., 2007; Singh et al., 2007).
Alterations or mutations of mtDNA are now emerging as new molecular markers for
detecting a variety of cancers (Tseng et al., 2006; Levenson, 2007). Various mutations cited
both in the non-coding and coding region of the mitochondrial genome showed risk towards
breast cancer (Tseng et al., 2006; Wong et al., 2007). A study by Zhu et al., (2005), showed
that most mutations and polymorphisms in breast cancer patients are located in the coding
region in contrast with a study by Tan et al., (2002) which showed that most mutations and
polymorphisms occurred in the D-loop region. Deletion at 4977 bp and D310 polymorphism
(a polynucleotide extending from 303-315 nucleotide positions within the non-coding
region) have been identified as the most frequent mutation hotspots found in malignant
breast tissue (Bianchi et al., 1995; Tan et al., 2002; Zhu et al., 2005; Aral et al., 2006).
Several studies reported the association of mtDNA 10398 polymorphism (substitution of A
allele to G allele at np 10398) with breast cancer in several populations (Canter et al., 2005;
Darvishi et al., 2006).
Despite the established role of the identified genes in both nuclear and mitochondrial DNA
in breast cancer susceptibility, the list of genetic factors involved in this disease is still
incomplete and more effort is needed to identify more bio-markers and genetic alterations
that would allow the selection of individuals with increase risk for intensive screening,
prevention and treatment programs (Kato et al., 2001; Esserman et al., 2007; Levenson,
2007).
1.2.3 Mitochondria DNA 10398 polymorphism
There are 2 major respiratory regions where ROS are produced, which are complex I and III
of the mitochondrial electron transport chain subunits. An A to G polymorphism at np 10398
has resulted in a nonconservative amino acid substitution of threonine (encoded by the A
allele) to alanine (encoded by the G allele) within the NADH dehydrogenase (ND3) subunit
of Complex I (Anderson et al., 1981: Kazuno et al., 2006). This polymorphism has also been
reported in altering both mitochondrial pH and intracellular calcium levels (Kazuno et al.,
2006; Kazuno et al., 2008), which have been associated with the modulation of ATP
production and apoptosis (Bernardi, 1992). The structural alteration and impairment of
Complex I are associated with the increased production of free radicals and increased risk of
several mitochondrial disorders such as Parkinson’s disease (Shoffner et al., 1993; Kosel et
al., 1998; Van der Walt et al., 2003) and bipolar disorders (Kato et al., 2001). This
polymorphism in combination with other polymorphisms has showed significantly increased
risk in patients with diabetes (Bhat et al., 2007; Rai et al., 2007) and also been reported in
thyroid carcinomas (Yeh et al., 2000).
The association of mitochondrial DNA 10398 polymorphism with breast cancer, was first
studied by Canter et al., (2005) and had shown that the risk of invasive breast cancer was
significantly higher for African-American women carrying the 10398A allele than non-
carriers. However, no association was observed among Caucasians. This result is also in
concordance with a study by Mims et al., (2006) in African-American men of prostate
cancer. The association of this polymorphism with risk towards breast cancer was also
presented in a study done on Indian population. This study had shown that the 10398A allele
carrier having risk towards breast cancer and esophageal cancer (Darvishi et al., 2006). In a
recent study carried on a larger sample group of the African-American women, no
association was detected between the 10398 polymorphism and breast cancer (Setiawan et
al., 2008). Opposite results were obtained in Polish population where the 10398G variant
showed significant high percentage in breast cancer patients compared to controls
(Czarnecka et al., 2009). Similar results were also obtained in non-Jewish European
American in combination with other variants (Covarrubias et al., 2008).
1.3 Single Nucleotide Polymorphisms (SNPs)
SNP is referred as sequence variation between individuals at a particular locus in the
genome. A single locus may be changed by substitution, deletion or insertion of a single
nucleotide. These variations are considered as SNP when at least 2 alleles have frequency of
more than 1% in a large or random population. Most SNPs are biallelic because the mutation
rate at a particular locus in the genome is extremely low, which is estimated 1 SNP per every
100-300 bp throughout the human genome (Bugalho et al., 2002; Borsting et al., 2007).
Currently, there are abundant of common SNPs available in each individual and 90% is in
the form of point mutation (a single base change) (Carracedo and Sanchez, 2005).
In mtDNA, SNP is termed by position according to the revised Cambridge reference
sequence (rCRS) (Andrews et al., 1999). Polymorphisms sites may confined within the
coding sequence or non-coding regions of genes (Ingman and Gyllensten, 2001). SNP within
coding region may not necessarily changes amino acid sequence of the protein that is
produced. Changes of amino acid sequence that forms the same protein is known as
synonymous or silent mutation while changes that leads to different polypeptide sequence is
called nonsynonymous. These changes may either be missense (produce different amino
acid) or nonsense (result in a premature stop codon). SNPs found in the mtDNA coding
region however are more likely to alter the biological of a protein. They were highly
abundance and have low mutation rate. Therefore, polymorphisms in coding region were
seen as best candidate to be expanded as mtDNA markers (Edrogan et al., 2001).
1.3.1 Minisequencing analysis of SNPs
Since the discovery of polymorphisms, a diverse range of DNA typing techniques have
continuously being developed (Jiang et al., 2004; Endicott et al., 2009). The techniques
include hybridization based (Jiang et al., 2004), enzyme based, primer extension (Li et al.,
1999) and sequencing.
Minisequencing is a much simplified version of sequencing applied in screening and
analyzing the different SNP loci within the mitochondrial genome (Quintans et al., 2004;
Carvalho and Pena, 2005). This method is based on polymerase-mediated single base
extension of oligonucleotide primer. Minisequencing does not need high quantity of DNA
templates and can withstand degraded samples (Bugalho et al., 2002; Quintans et al., 2004;
Borsting et al., 2007). Minisequencing analysis such as solid-phase (Syvanen et al., 1990),
microarray based (Liljedahl et al., 2004) and SNaPshot™ (Krone et al., 2002) are among the
emerging techniques for mtDNA SNPs analyses.
SNaPshot™ is an elevated sensitivity technique for SNP screening that provides a rapid,
robust and high accuracy result. The processing and data analysis is fully automated and can
be easily interpreted (Krone et al., 2002). SNaPshot™ analysis can interrogate up to 10
SNPs at known locations on 1 to 10 DNA templates in a single tube. The primer for this
analysis was designed to be just one nucleotide shorter from the polymorphic site. In
multiplex reaction, the primer length differed by 2-4 nucleotides to avoid overlapping
between the SNaPshot™ products on the electropherogram. The primer will be extended by
a single fluorescent labeled ddNTP complimentary to the variant base in the template.
Application of this technique enables rapid detection of polymorphisms and suitable as a
mutation screening method for several diseases.
1.3.2 Immunohistochemistry analysis (IHC)
Detection of cell death in cells and tissues has becoming important in cancer studies as
defects in the thresholds has shown to results in several diseases and cancers. Apoptosis
occurs through a complex regulated signaling cascades leading to changes of cell’s
morphology, biochemical and molecular, thus provides many opportunities to exploit the
key elements regulating apoptosis. Many assays have been developed to measures the
apoptosis elements such as DNA fragmentation, membrane alterations, caspases and
mitochondrial changes. The methods were successfully used to detect apoptosis in
population of cells and individual cells. However, most of the methods required a large
quantity of cells and not applicable to histological sections of archival paraffin-embedded
